$INBXInhibrx Biosciences, Inc.

Active trials

• phase2Study of INBRX-109 in Conventional Chondrosarcomaactive not recruitingn=206
• phase3INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCCactive not recruitingn=410
• phase1Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomasrecruitingn=321
• phase2Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)active not recruitingn=296
• phase1Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancerterminatedn=160